{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:40:28Z","timestamp":1795084828887,"version":"4.10.2"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>The cellular immune system is of pivotal importance with regard to the response to severe infections. Monocytes\/macrophages are considered key immune cells in infections and downregulation of the surface expression of monocytic human leukocyte antigen-DR (mHLA-DR) within the major histocompatibility complex class II reflects a state of immunosuppression, also referred to as injury-associated immunosuppression. As the role of immunosuppression in coronavirus disease 2019 (COVID-19) is currently unclear, we seek to explore the level of mHLA-DR expression in COVID-19 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>In a preliminary prospective monocentric observational study, 16 COVID-19\u2013positive patients (75% male, median age: 68 [interquartile range 59\u201375]) requiring hospitalization were included. The median Acute Physiology and Chronic Health Evaluation-II (APACHE-II) score in 9 intensive care unit (ICU) patients with acute respiratory failure was 30 (interquartile range 25\u201332). Standardized quantitative assessment of HLA-DR on monocytes (cluster of differentiation 14+ cells) was performed using calibrated flow cytometry at baseline (ICU\/hospital admission) and at days 3 and 5 after ICU admission. Baseline data were compared to hospitalized noncritically ill COVID-19 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      While normal mHLA-DR expression was observed in all hospitalized noncritically ill patients (n = 7), 89% (8 of 9) critically ill patients with COVID-19\u2013induced acute respiratory failure showed signs of downregulation of mHLA-DR at ICU admission. mHLA-DR expression at admission was significantly lower in critically ill patients (median, [quartiles]: 9280 antibodies\/cell [6114, 16,567]) as compared to the noncritically ill patients (30,900 antibodies\/cell [26,777, 52,251]), with a median difference of 21,508 antibodies\/cell (95% confidence interval [CI], 14,118\u201342,971),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .002. Reduced mHLA-DR expression was observed to persist until day 5 after ICU admission.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>When compared to noncritically ill hospitalized COVID-19 patients, ICU patients with severe COVID-19 disease showed reduced mHLA-DR expression on circulating CD14+ monocytes at ICU admission, indicating a dysfunctional immune response. This immunosuppressive (monocytic) phenotype remained unchanged over the ensuing days after ICU admission. Strategies aiming for immunomodulation in this population of critically ill patients should be guided by an immune-monitoring program in an effort to determine who might benefit best from a given immunological intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1213\/ane.0000000000005044","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T17:30:54Z","timestamp":1591378254000},"page":"993-999","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":82,"title":["Reduced Monocytic Human Leukocyte Antigen-DR Expression Indicates Immunosuppression in Critically Ill COVID-19 Patients"],"prefix":"10.1213","volume":"131","author":[{"given":"Thibaud","family":"Spinetti","sequence":"first","affiliation":[{"name":"Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Hirzel","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Fux","sequence":"additional","affiliation":[{"name":"University Institute of Clinical Chemistry, Inselspital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura N.","family":"Walti","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Schober","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, Amsterdam University Medical Centres, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Stueber","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus M.","family":"Luedi","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg C.","family":"Schefold","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,6,4]]},"reference":[{"key":"R1-20250227","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/ni.3693","article-title":"Social network architecture of human immune cells unveiled by quantitative proteomics.","volume":"18","author":"Rieckmann","year":"2017","journal-title":"Nat Immunol"},{"key":"R2-20250227","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nri3552","article-title":"Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy.","volume":"13","author":"Hotchkiss","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"R3-20250227","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40635-017-0163-0","article-title":"Assessment of immune organ dysfunction in critical illness: utility of innate immune response markers.","volume":"5","author":"Pfortmueller","year":"2017","journal-title":"Intensive Care Med Exp"},{"key":"R4-20250227","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S1473-3099(19)30567-5","article-title":"Current gaps in sepsis immunology: new opportunities for translational research.","volume":"19","author":"Rubio","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"R5-20250227","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1097\/CCM.0b013e31818bdd8f","article-title":"Consider delayed immunosuppression into the concept of sepsis.","volume":"36","author":"Schefold","year":"2008","journal-title":"Crit Care Med"},{"key":"R6-20250227","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrneph.2017.165","article-title":"Advances in the understanding and treatment of sepsis-induced immunosuppression.","volume":"14","author":"Venet","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"R7-20250227","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.mehy.2008.03.022","article-title":"Sepsis: time has come to focus on the later stages.","volume":"71","author":"Schefold","year":"2008","journal-title":"Med Hypotheses"},{"key":"R8-20250227","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nri3818","article-title":"The ins and outs of MHC class II-mediated antigen processing and presentation.","volume":"15","author":"Roche","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"R9-20250227","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/cc9184","article-title":"Assessment of monocytic HLA-DR expression in ICU patients: analytical issues for multicentric flow cytometry studies.","volume":"14","author":"Monneret","year":"2010","journal-title":"Crit Care"},{"key":"R10-20250227","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1007\/s00134-010-1965-7","article-title":"Measurement of monocytic HLA-DR (mHLA-DR) expression in patients with severe sepsis and septic shock: assessment of immune organ failure.","volume":"36","author":"Schefold","year":"2010","journal-title":"Intensive Care Med"},{"key":"R11-20250227","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1373\/clinchem.2005.052639","article-title":"Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study.","volume":"51","author":"D\u00f6cke","year":"2005","journal-title":"Clin Chem"},{"key":"R12-20250227","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.annfar.2010.02.015","article-title":"Low monocytic HLA-DR expression and risk of secondary infection.","volume":"29","author":"Ch\u00e9ron","year":"2010","journal-title":"Ann Fr Anesth Reanim"},{"key":"R13-20250227","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00134-006-0204-8","article-title":"Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock.","volume":"32","author":"Monneret","year":"2006","journal-title":"Intensive Care Med"},{"key":"R14-20250227","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.coi.2013.05.006","article-title":"Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies.","volume":"25","author":"Venet","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"R15-20250227","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.2011.1829","article-title":"Immunosuppression in patients who die of sepsis and multiple organ failure.","volume":"306","author":"Boomer","year":"2011","journal-title":"JAMA"},{"key":"R16-20250227","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s00134-003-1666-6","article-title":"Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis.","volume":"29","author":"Nierhaus","year":"2003","journal-title":"Intensive Care Med"},{"key":"R17-20250227","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1164\/rccm.200903-0363OC","article-title":"Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial.","volume":"180","author":"Meisel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"R18-20250227","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1186\/s12879-019-4526-x","article-title":"Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series.","volume":"19","author":"Payen","year":"2019","journal-title":"BMC Infect Dis"},{"key":"R19-20250227","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/shk.0b013e31804f5921","article-title":"A novel selective extracorporeal intervention in sepsis: immunoadsorption of endotoxin, interleukin 6, and complement-activating product 5a.","volume":"28","author":"Schefold","year":"2007","journal-title":"Shock"},{"key":"R20-20250227","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13054-020-2774-1","article-title":"Immune biomarker-based enrichment in sepsis trials.","volume":"24","author":"Spinetti","year":"2020","journal-title":"Crit Care"},{"key":"R21-20250227","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China.","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"R22-20250227","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/M20-0504","article-title":"The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application.","volume":"172","author":"Lauer","year":"2020","journal-title":"Ann Intern Med"},{"key":"R23-20250227","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia.","volume":"382","author":"Li","year":"2020","journal-title":"N Engl J Med"},{"key":"R24-20250227","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(20)30528-6","article-title":"Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures.","volume":"395","author":"Pung","year":"2020","journal-title":"Lancet"},{"key":"R25-20250227","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention.","volume":"20","author":"Tay","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"R26-20250227","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1213\/ANE.0000000000004373","article-title":"Two-sample unpaired t tests in medical research.","volume":"129","author":"Schober","year":"2019","journal-title":"Anesth Analg"},{"key":"R27-20250227","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1213\/ANE.0000000000003424","article-title":"Regression: the apple does not fall far from the tree.","volume":"127","author":"Vetter","year":"2018","journal-title":"Anesth Analg"},{"key":"R28-20250227","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1213\/ANE.0000000000004627","article-title":"Confounding in observational research.","volume":"130","author":"Schober","year":"2020","journal-title":"Anesth Analg"}],"container-title":["Anesthesia &amp; Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000005044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:35:55Z","timestamp":1786113355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000005044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0000000000005044","relation":{},"ISSN":["0003-2999"],"issn-type":[{"value":"0003-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,4]]}}}